Treatment depends on the stage of the disease, the tumor’s biological features, inherited genetic changes, previous treatments, and the patient’s overall health.
The main treatment options include chemotherapy, surgery, radiation therapy, immunotherapy, targeted medications, antibody-drug conjugates, and clinical trials.
Chemotherapy
Chemotherapy remains a cornerstone of TNBC treatment because it can destroy rapidly dividing cancer cells throughout the body.
Common medications or combinations include:
- Paclitaxel and docetaxel.
- Carboplatin and cisplatin.
- Doxorubicin and epirubicin.
- Cyclophosphamide.
- Capecitabine.
- Gemcitabine and eribulin, particularly in advanced disease.
The drugs used depend on the treatment setting. Some patients receive chemotherapy before surgery to shrink a tumor, while others receive it afterward to reduce the risk of recurrence.
In metastatic TNBC, chemotherapy may shrink tumors, relieve symptoms, or slow disease progression. It may be given as a single medication or as a combination, depending on the situation.
Side effects vary but may include fatigue, nausea, hair loss, low blood counts, infection risk, and nerve damage. Treatment teams can often provide medications and other supportive measures to manage these effects.
Surgery and Radiation Therapy
For early-stage TNBC, surgery may involve a lumpectomy or mastectomy, along with appropriate evaluation of nearby lymph nodes.
Radiation therapy may be recommended after lumpectomy and in some cases after mastectomy, particularly when lymph nodes are involved or other features increase the risk of local recurrence.
These treatments address cancer in the breast and nearby tissues. Systemic therapies, such as chemotherapy and immunotherapy, address cancer cells that may exist elsewhere in the body.
For metastatic TNBC, surgery is not usually the primary treatment for controlling distant disease, but surgery or radiation can sometimes relieve symptoms or manage specific areas of cancer.
Immunotherapy: Helping the Immune System Fight Cancer
Immunotherapy has been a major advance in TNBC treatment.
The immune system can recognize and attack abnormal cells, but cancers may develop ways to evade immune detection. Some cancer cells use proteins such as PD-L1 to activate inhibitory signals that reduce immune-cell activity.
Pembrolizumab, known by the brand name Keytruda, is an immune checkpoint inhibitor that blocks the PD-1 pathway. This can help immune cells recognize and attack cancer cells.
Immunotherapy is not appropriate for every person with TNBC, but it has become an important option in specific treatment settings.
For high-risk early-stage TNBC: Pembrolizumab can be given with chemotherapy before surgery and continued after surgery. In the KEYNOTE-522 clinical trial, five-year overall survival was approximately 86.6% in the group receiving pembrolizumab plus chemotherapy, compared with 81.7% in the chemotherapy-only comparison group. These results demonstrate a meaningful benefit in the studied population.
For certain metastatic TNBC: Pembrolizumab combined with chemotherapy has been used for tumors meeting the required PD-L1 criteria. PD-L1 testing helps determine whether this approach is appropriate.
Immunotherapy can have side effects different from those of chemotherapy. These include fatigue, rash, diarrhea, and inflammation of organs such as the thyroid, lungs, liver, or intestines. Some immune-related complications can be serious and require prompt medical evaluation.
Immunotherapy does not work for everyone, and its benefits must be weighed against its risks.
Targeted Therapy for Inherited BRCA Mutations
Some people with TNBC have an inherited mutation in the BRCA1 or BRCA2 gene. These genes normally help repair damaged DNA. When one has a harmful inherited mutation, cancer cells may have difficulty repairing certain types of DNA damage.
PARP inhibitors take advantage of this weakness.
Two examples are:
- Olaparib (Lynparza).
- Talazoparib (Talzenna).
These medications can be used in eligible patients with HER2-negative breast cancer and specific BRCA mutations. Olaparib can also be used after treatment for selected patients with high-risk early-stage disease who meet eligibility criteria.
Genetic counseling and germline testing are important considerations for people diagnosed with TNBC, including younger patients and those with relevant personal or family histories.
Testing can influence treatment choices and may also provide useful information for biological relatives.
Antibody-Drug Conjugates: A Major Treatment Advance
Antibody-drug conjugates, or ADCs, are medications that combine an antibody designed to recognize a particular target with a cancer-killing drug.
The antibody helps deliver the drug to cancer cells, although these medications can also affect healthy cells and cause significant side effects.
Two important ADCs used in TNBC care are:
- Sacituzumab govitecan (Trodelvy).
- Datopotamab deruxtecan (Datroway).
These treatments have expanded options for people with advanced TNBC, including patients whose disease cannot be removed surgically or has spread to distant organs.
In June 2026, the U.S. Food and Drug Administration (FDA) approved sacituzumab govitecan as a first-line option for certain adults with unresectable locally advanced or metastatic TNBC. This includes use alone for people who are not candidates for PD-1 or PD-L1 inhibitor treatment and use with pembrolizumab for eligible tumors meeting the PD-L1 criterion.
In May 2026, the FDA also approved datopotamab deruxtecan for adults with unresectable or metastatic TNBC who are not candidates for PD-1 or PD-L1 inhibitor therapy. In its pivotal trial, median progression-free survival was 10.8 months with datopotamab deruxtecan versus 5.6 months with the chemotherapy comparison group. These are trial-specific results, not predictions for an individual patient.
Potential side effects vary by medication. Sacituzumab govitecan can cause significant diarrhea and low white blood cell counts. Datopotamab deruxtecan can cause mouth sores, eye-related problems, and inflammation or scarring of lung tissue. Close monitoring is important.
New and Emerging Treatments for TNBC
Research continues to explore ways to prevent recurrence, improve responses to existing medications, and develop new treatment approaches for resistant disease.
Some promising areas include:
- New antibody-drug conjugates: Researchers are studying additional targets and drug combinations to improve cancer-cell delivery and treatment effectiveness.
- Next-generation immunotherapy: Studies are investigating new immune checkpoint targets, combinations of immune therapies, and ways to make tumors more responsive to immune attack.
- Personalized treatment based on genetics: Tumor sequencing may identify changes that make a patient eligible for a targeted treatment or clinical trial.
- Circulating tumor DNA (ctDNA): Researchers are evaluating whether tiny amounts of tumor DNA in the blood can identify residual disease or predict recurrence before it becomes visible on scans. This is an evolving area and is not a universal replacement for standard follow-up.
- New strategies for residual disease: Trials are exploring how best to treat cancer that remains after chemotherapy and immunotherapy, when recurrence risk may be higher.
Some approaches are already approved for specific patient groups, while others remain investigational. A promising early study does not necessarily mean a treatment is ready for routine use.
Clinical trials can be especially valuable for TNBC because the disease has fewer traditional treatment targets and researchers continue to look for ways to improve long-term outcomes.
Patients can ask their oncologist whether a clinical trial is appropriate at diagnosis, after surgery, or if the disease returns or progresses.
Citations.
Triple Negative Breast Cancer Foundation
Mayo Clinic
Metastatic Breast Cancer Alliance
NIH
CDC